Skip navigation links
Peter Gulick, DO FACP, FIDSA, FACOI

Peter Gulick, DO FACP, FIDSA, FACOI

Professor of Medicine

Take care of HIV/AIDS patients as well as Hepatitis C, B patients at 3 sites in Michigan

Get In Touch

Area of Expertise

Hepatitis C Hiv/Aids Hepatitis B

Biography

Peter Gulick is currently an associate professor of medicine at Michigan State University, College of Osteopathic Medicine, and serves as adjunct faculty in the College of Human Medicine and the College of Nursing.

He received training in two primary specialties: infectious diseases at the Cleveland Clinic Foundation and medical oncology at Roswell Park Memorial Institute.

Gulick is director of the MSU HIV/Hepatitis clinic where his primary area of interest is HIV therapy, as well as hepatitis ... B, hepatitis C and co-infection therapy.

In addition to teaching, Gulick has cared for HIV patients for 20 years and hepatitis C patients for 10 years.

He has served on the Lung Cancer Advisory Committee through the State of Michigan's Department of Community Health , as well as the HIV/AIDS Prevention and Intervention Section, the Michigan Cancer Consortium and the Region 1 Smallpox Planning Team.

Read More

Education

Cleveland Clinic Foundation: Infectious Diseases, | 1983

Roswell Park Memorial Institute: Medical Oncology, | 1981

Cleveland Clinic Foundation: Internal Medicine, | 1980

Detroit Osteopathic Hospital: Internship, | 1977

Midwestern University: D.O., | 1976

Michigan State University: M.D.,

University of Michigan,: M.A., Health Managements and Policy

Selected Press

MSU Infectious Disease Specialist Weighs In On Pfizer COVID-19 Vaccine Announcement

WKAR | 2020-11-11

The drug manufacturer Pfizer announced promising test results on a possible COVID-19 vaccine this week. It’s being reported that the vaccine could be submitted to the FDA for emergency use authorization as soon as the third week of November. WKAR’s Scott Pohl talks with MSU infectious disease specialist Dr. Peter Gulick about the Pfizer announcement.

Preflight Covid-19 testing is on the rise — the question is whether it works

CNBC | 2020-10-14

In calling for preflight testing last month, the IATA said that, “deployable solutions are expected in the coming weeks.” Medical experts say that may be premature. Polymerase chain reaction tests, also called PCR, can more accurately diagnose positive cases, said Dr. Peter Gulick, an infectious disease expert at Michigan State University. But those tests, which rely on a nasal swap, throat swab or saliva, “are run in a lab so it may take days to come back, and a patient may get infected during that time,” he said. That is the rub with PCR tests. Test too early, and a person’s chances of being infected after the test increase. Test too late, and the results may not be ready by departure time.

We Asked Doctors to Weigh In on the Biggest Coronavirus Myths Circulating Right Now

Yahoo! Finance | 2020-10-03

FACT: Even if you don't have symptoms, you can still be contagious. “It's possible that 70% to 80% of people may have mild to no symptoms, but I would still be very cautious because you may still be infectious,” says Peter Gulick, infectious disease expert at Michigan State University. What common symptoms should you expect? That landscape changes by the day, but as of now a high fever, dry cough, shortness of breath, and loss of sense of smell or taste are biggies to look out for. Some people are also thought to exhibit gastrointestinal signs like diarrhea, body aches, and upper respiratory symptoms like congestion. Keep yourself healthy by washing your hands regularly and staying inside.

Should You Invest in a UV Light to Sanitize Surfaces Like Your Phone? We Asked Experts

Pop Sugar | 2020-09-29

Does UV Light Actually Kill the Coronavirus? Peter Gulick, associate professor of medicine at Michigan State University, said that, while ultraviolet Cis the most effective form of UV light for combatting pathogens, "it's also potentially toxic to skin and mucous membranes."

Media Assets